Corticosteroids in the prevention of graft-vs-host disease after allogeneic myeloablative stem cell transplantation: A systematic review and meta-analysis

Leukemia

Volumn 22, Issue 9, 2008, Pages 1801-1803

  Quellmann, S ^a   Schwarzer, G ^b   Hubel K ^a   Engert, A ^a   Bohlius, J ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN A; METHOTREXATE; METHYLPREDNISOLONE;

ADD ON THERAPY; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CHEMOPROPHYLAXIS; CLINICAL TRIAL; DATA ANALYSIS; DRUG DOSE REDUCTION; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL; HUMAN; INFECTIOUS COMPLICATION; INFORMATION RETRIEVAL; META ANALYSIS; MYELOABLATIVE CONDITIONING; OUTCOME ASSESSMENT; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; STATISTICAL ANALYSIS; SURVIVAL; SYSTEMATIC REVIEW;

ADRENAL CORTEX HORMONES; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MYELOABLATIVE AGONISTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 51649107563     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2008.105     Document Type: Review

References (8)

1. Atkinson K, Biggs J, Concannon A, Dodds A, Young S, Wilson F et al A prospective randomised trial of cyclosporin and methotrexate vs cyclosporin, methotrexate and prednisolone for prevention of graft-vs-host disease after HLA-identical sibling marrow transplantation for haematological malignancy. Aust N Z J Med 1991; 21: 850-856.
2. Chao NJ, Snyder DS, Jain M, Wong RM, Niland JC, Negrin RS et al. Equivalence of 2 effective graft-vs-host disease prophylaxis regimens: results of a prospective double-blind randomized trial. Biol Blood Marrow Transplant 2000; 6: 254-261.
3. Deeg HJ, Lin D, Leisenring W, Boeckh M, Anasetti C, Appelbaum FR et al. Cyclosporine or cyclosporine plus methylprednisolone for prophylaxis of graft-vs-host disease: A prospective, randomized trial. Blood 1997; 89: 3880-3887.
4. Ruutu T, Volin L, Parkkali T, Juvonen E, Elonen E. Cyclosporine, methotrexate, and methylprednisolone compared with cyclosporine and methotrexate for the prevention of graft-vs-host disease in bone marrow transplantation from HLA-identical sibling donor: A prospective randomized study. Blood 2000; 96: 2391-2398.
5. Storb R, Pepe M, Anasetti C, Appelbaum FR, Beatty P, Doney K et al What role for prednisone in prevention of acute graft-vs-host disease in patients undergoing marrow transplants? Blood 1990; 76: 1037-1045.
6. Deeg H, Flowers M, Leisenring W, Appelbaum F, Martin P, Storb R. Cyclosporine (CSP) or CSP plus methylprednisolone for graft-vs-host disease prophylaxis in patients with high-risk lymphohemopoietic malignancies: Long-term follow-up of a randomized trial. Blood 2000; 96: 1194-1195.
7. Ruutu T, Volin L, Juvonen E, Parkkali T, Elonen E, Nihtinen A. Cyclosporine, methotrexate and methylprednisolone compared with cyclosporine and methotrexate for the prevention of graft-vs-host disease in bone marrow transplantation from HLA-identical sibling donor: long-term follow-up of a randomized study (abstract). Bone Marrow Transplant 2003; 31 (Suppi 1): S138.
8. Sayer HG, Longton G, Bowden R, Pepe M, Storb R. Increased risk of infection in marrow transplant patients receiving methylprednisolone for graft-vs-host disease prevention. Blood 1994; 84: 1328-1332.